Annual Statements Open main menu

PROCYON CORP - Quarter Report: 2021 December (Form 10-Q)

pcyn20211231_10q.htm
 

 

UNITED STATES SECURITIES & EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For Quarterly Period Ended December 31, 2021

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from         to

 

Commission File Number: 0-17449

 

PROCYON CORPORATION

(Exact Name of Registrant as specified in its charter)

 

Colorado59-3280822
(State of Incorporation)(I.R.S. Employer Identification Number)

 

164 Douglas Road East, Oldsmar, FL 34677

(Address of Principal Executive Offices)

 

(727) 447-2998

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

None

None

None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐Accelerated filer ☐
Non-accelerated filer ☐Smaller reporting company ☒
Emerging growth company ☐ 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: Common stock, no par value; 8,087,388 shares outstanding as of February 4, 2022.

 

 

 
 

 

 
Item Page
   
PART I. - FINANCIAL INFORMATION  
   

ITEM 1. FINANCIAL STATEMENTS

3

   

Index to Financial Statements

 
   
Financial Statements:  
   

Consolidated Balance Sheets

3

Consolidated Statements of Operations

4

Consolidated Statements of Changes in Stockholders’ Equity

5

Consolidated Statements of Cash Flows

6

   

Notes to Consolidated Financial Statements

7

   

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

13

   

ITEM 4. CONTROLS AND PROCEDURES

17

   

PART II. - OTHER INFORMATION

 
   

ITEM 5. OTHER INFORMATION

17

   

ITEM 6. EXHIBITS

18

   

SIGNATURES

19

 

 

 

 

PROCYON CORPORATION & SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31, 2021 and June 30, 2021

 

  

(unaudited)

  

(audited)

 

 

 

December 31,

  

June 30,

 
  

2021

  

2021

 
ASSETS        
         

CURRENT ASSETS

        

Cash

 $806,574  $1,226,522 

Certificates of Deposit, plus accrued interest

  280,840   280,438 

Accounts Receivable, less allowance for doubtful accounts of $4,925 and $9,408, respectively.

  418,591   497,358 

Inventories

  853,738   591,058 

Prepaid Expenses

  247,581   276,251 

TOTAL CURRENT ASSETS

  2,607,324   2,871,627 
         

PROPERTY AND EQUIPMENT, NET

  143,869   109,275 
         

OTHER ASSETS

        

Deposits

  27,899   3,235 

Inventories

  181,777   263,280 

Intangible Asset

  17,000   17,000 

ROU Assets - Operating Leases

  794,872   882,344 

Deferred Tax Asset, net valuation allowance of $31,960 and $0, respectively.

  82,308   120,430 
   1,103,856   1,286,289 
         

TOTAL ASSETS

 $3,855,049  $4,267,191 
         
         

LIABILITIES AND STOCKHOLDERS' EQUITY

        
         

CURRENT LIABILITIES

        

Accounts Payable

 $38,221  $167,588 

Lease Liability, Current

  158,247   154,022 

Accrued Expenses

  232,389   413,977 

TOTAL CURRENT LIABILITIES

  428,857   735,587 
         

LONG TERM LIABILITIES

        

Lease Liability - Operating Leases

  573,528   653,860 

TOTAL LONG TERM LIABILITIES

  573,528   653,860 
         

TOTAL LIABILITIES

  1,002,385   1,389,447 
         

COMMITMENTS AND CONTINGENCIES (NOTE I)

  -   - 
         

STOCKHOLDERS' EQUITY

        

Preferred Stock, 496,000,000 shares authorized, none issued.

  -   - 

Series A Cumulative Convertible Preferred Stock, no par value; 4,000,000 shares authorized; 167,100 shares issued and outstanding.

  126,860   126,860 

Common Stock, no par value, 80,000,000 shares authorized; 8,087,388 shares issued and outstanding.

  4,444,766   4,444,766 

Paid-in Capital

  35,564   35,564 

Accumulated Deficit

  (1,754,526)  (1,729,446)

TOTAL STOCKHOLDERS' EQUITY

  2,852,664   2,877,744 
         

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

 $3,855,049  $4,267,191 

 

The accompanying notes are an integral part of these financial statements.

 

-3-

 

 

PROCYON CORPORATION & SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

Three and Six Months Ended December 31, 2021 and 2020

 

  

(unaudited)

  

(unaudited)

  

(unaudited)

  

(unaudited)

 
  

Three Months

  

Three Months

  

Six Months

  

Six Months

 
  

Ended

  

Ended

  

Ended

  

Ended

 
  

Dec. 31, 2021

  

Dec. 31, 2020

  

Dec. 31, 2021

  

Dec. 31, 2020

 
                 

NET SALES

 $1,330,636  $1,174,405  $2,520,613  $2,420,648 
                 

COST OF SALES

  411,914   328,571   740,167   662,892 
                 

GROSS PROFIT

  918,722   845,834   1,780,446   1,757,756 
                 

OPERATING EXPENSES

                

Salaries and Benefits

  497,261   414,467   936,721   826,721 

Selling, General and Administrative

  475,371   326,492   831,751   609,612 
   972,632   740,959   1,768,472   1,436,333 
                 

INCOME / (LOSS) FROM OPERATIONS

  (53,910)  104,875   11,974   321,423 
                 

OTHER INCOME (EXPENSE)

                

Interest Income / (Expense)

  697   (1,017)  1,068   (733)
   697   (1,017)  1,068   (733)
                 

INCOME / (LOSS) BEFORE INCOME TAXES

  (53,213)  103,858   13,042   320,690 
                 

INCOME TAX (EXPENSE) / BENEFIT

  (14,349)  (29,545)  (38,122)  (27,281)
                 

NET INCOME / (LOSS)

  (67,562)  74,313   (25,080)  293,409 
                 

Dividend requirements on preferred stock

  (4,178)  (4,178)  (8,356)  (8,356)
                 

Basic net income (loss) available to common shares

 $(71,740) $70,135  $(33,436) $285,053 
                 

Basic net income (loss) per common share

 $(0.01) $0.01  $(0.00) $0.04 
                 

Weighted average number of common shares outstanding

  8,087,388   8,087,388   8,087,388   8,087,388 
                 

Diluted net income (loss) per common share

 $(0.01) $0.01  $(0.00) $0.03 
                 

Weighted average number of common shares outstanding, diluted

  8,087,388   8,319,488   8,087,388   8,319,488 

 

The accompanying notes are an integral part of these financial statements.

 

-4-

 

 

PROCYON CORPORATION & SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

For the Six Months Ended December 31, 2021 and 2020

 

Six Months Ended December 31, 2021

 

Preferred Stock

  

Common Stock

  

Paid-In

  

Accumulated

  

Total

Stockholders'

 
  

Shares

  

Amount

  

Shares

  

Amount

  

Capital

  

Deficit

  

Equtiy

 

Balance, June 30, 2021

  167,100  $126,860   8,087,388  $4,444,766  $35,564  $(1,729,446) $2,877,744 
                             

Net Income

  -   -   -   -   -   42,482   42,482 
                             

Balance, September 30, 2021

  167,100   126,860   8,087,388   4,444,766   35,564   (1,686,964) $2,920,226 
                             

Net Income (Loss)

  -   -   -   -   -   (67,562)  (67,562)
                             

Balance, December 31, 2021

  167,100  $126,860   8,087,388  $4,444,766  $35,564  $(1,754,526) $2,852,664 

 

Six Months Ended December 31, 2020

 

Preferred Stock

    Common Stock    

Paid-In

   

Accumulated

   

Total

Stockholders'

 
   

Shares

   

Amount

   

Shares

   

Amount

   

Capital

   

Deficit

   

Equtiy

 

Balance, June 30, 2020

    167,100     $ 126,860       8,087,388     $ 4,444,766     $ 15,885     $ (2,423,795 )   $ 2,163,716  
                                                         

Net Income

    -       -       -       -       -       219,096       219,096  
                                                         

Balance, September 30, 2020

    167,100     $ 126,860       8,087,388     $ 4,444,766     $ 15,885     $ (2,204,699 )   $ 2,382,812  
                                                         

Net Income (Loss)

    -       -       -       -       -       74,313       74,313  
                                                         

Balance, December 31, 2020

    167,100     $ 126,860       8,087,388     $ 4,444,766     $ 15,885     $ (2,130,386 )   $ 2,457,125  

 

The accompanying notes are an integral part of these financial statements.

 

-5-

 

 

PROCYON CORPORATION & SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Six Months Ending December 31, 2021 and 2020

 

   

(unaudited)

December 31,

2021

   

(unaudited)

December 31,

2020

 

CASH FLOWS FROM OPERATING ACTIVITIES

               
                 

Net (Loss) / Income

  $ (25,080 )   $ 293,409  

Adjustments to reconcile net income to net cash (used in) / provided by operating activities:

               

Depreciation

    17,614       22,731  

Right of Use Asset Amortization

    87,472       21,400  

Deferred Income Taxes

    6,162       83,920  

Valuation Allowance

    31,960       (56,639 )
Accrued Interest on Certificates of Deposit     (402 )     (280 )
Decrease (increase) in:                

Accounts Receivable

    78,767       (148,683 )

Deposits

    (24,664 )  

 

Inventory

    (181,177 )     (60,702 )

Prepaid Expenses

    28,670       (18,709 )
Increase (decrease) in:                

Accounts Payable

    (129,367 )     (53,686 )

Accrued Expenses

    (181,588 )     (101,817 )

NET CASH (USED IN) OPERATING ACTIVITIES

    (291,633 )     (19,056 )
                 

CASH FLOW FROM INVESTING ACTIVITIES

               
                 

Purchase of property & equipment

    (52,208 )     (10,027 )

NET CASH (USED IN) INVESTING ACTIVITIES

    (52,208 )     (10,027 )
                 

CASH FLOW FROM FINANCING ACTIVITIES

               
                 

Purchase of CD

 

   

 
Increase in Operating Lease Liability     (76,107 )     10,231  

NET CASH PROVIDED BY / (USED IN) FINANCING ACTIVITIES

    (76,107 )     10,231  
                 

NET CHANGE IN CASH

    (419,948 )     (18,852 )
                 

CASH AT BEGINNING OF PERIOD

    1,226,522       665,834  
                 

CASH AT END OF PERIOD

  $ 806,574     $ 646,982  
                 

SUPPLEMENTAL DISCLOSURES

               

Interest Paid

  $     $  
Taxes Paid   $     $  

 

NONCASH DISCLOSURE

 

 

During the six months ended December 31, 2019, we established a Right of Use Asset in the amount of $73,719 and corresponding Lease Liability in the amount of $80,659. The cumulative adjustment of $6,938 at July 1, 2019 was made to accumulated deficit pursuant to ASC 842.

 

During the quarter ended September 30, 2020, we increased a Right of Use Asset and corresponding lease liability in the amount of $34,798

 

The accompanying notes are an integral part of these financial statements.

 

- 6-

 

Notes to Financial Statements

 

 

NOTE A - SUMMARY OF ACCOUNTING POLICIES

 

The interim consolidated financial statements included herein have been prepared by the Company without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with generally accepted accounting principles ("GAAP") have been condensed or omitted as allowed by such rules and regulations. The Company believes that the disclosures are adequate to make the information presented not misleading. These consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements dated June 30, 2021, and as contained in the Company's annual report on Form 10-K, as filed with the Securities and Exchange Commission on October 8, 2021 and amended on Form 10-K/A, as filed with the Securities and Exchange Commission on November 12, 2021, which contain certain restatements to the June 30, 2021 financial statements. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

 

Management of the Company has prepared the accompanying unaudited condensed consolidated financial statements prepared in conformity with generally accepted accounting principles, which require the use of management estimates, contain all adjustments (including normal recurring adjustments) necessary to present fairly the operations and cash flows for the period presented and to make the financial statements not misleading.

 

STOCK-BASED COMPENSATION

 

Stock based compensation is accounted for in accordance with Topic 718 - Compensation - Stock Compensation in the Accounting Standards Codification. Pursuant to Topic 718, all share-based payments to employees, including grants of employee stock options, are to be recognized in the statement of operations based upon their fair values. Topic 718 rescinds the acceptance of pro forma disclosure. In December 2009, our shareholders approved the adoption of a new stock option plan, providing the Company a continued means of offering stock-based compensation.

 

On December 31, 2021, there were 65,000 outstanding options to purchase shares of our common stock granted under our prior 2009 Stock Option Plan. There were 50,000 outstanding options to purchase shares of our common stock granted under our 2020 Stock Option Plan.

 

The fair value of a stock option is determined using the Black-Scholes option-pricing model, which values options based on the stock price at the grant date, the expected life of the option, the estimated volatility of the stock, the expected dividend payments, and the risk-free interest rate over the life of the option. There were no options granted during the quarter ended December 31, 2021.

 

The Black-Scholes option valuation model was developed for estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Because option valuation models require the use of subjective assumptions, changes in these assumptions can materially affect the fair value of the options. Our options do not have the characteristics of traded options, therefore, the option valuation models do not necessarily provide a reliable measure of the fair value of our options.

 

- 7-

 

EARNINGS PER SHARE

 

Basic earnings per share (EPS) is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that would occur if dilutive securities such as stock options and other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that then shared in earnings. We use the treasury stock method to compute potential common shares from stock options and the as-if-converted method to compute potential common shares from Preferred Stock.

 

For the three and six months ended December 31, 2021, the potential dilutive effects of the preferred stock and stock options were included in the weighted-average shares outstanding.

 

 

NOTE B - INVENTORIES

 

Inventories consisted of the following:

 

  

December 31,

2021

  
June 30,
2021
 
         

Finished Goods

 $834,560  $683,771 

Raw Materials

  200,955   170,567 
  $1,035,515  $854,338 

 

At December 31, 2021 and June 30, 2021, respectively, $181,777 and $263,280 of our inventory was considered non-current as it will not be used within a one year period.
 
 
NOTE C - STOCKHOLDERS' EQUITY

 

During January 1995, the Company's Board of Directors authorized the issuance of up to 4,000,000 shares of Series A Cumulative Convertible Preferred Stock ("Series A Preferred Stock"). The preferred stockholders are entitled to receive, as and if declared by the board of directors, quarterly dividends at an annual rate of $.10 per share of Series A Preferred Stock per annum. Dividends will accrue without interest and will be cumulative from the date of issuance of the Series A Preferred Stock and will be payable quarterly in arrears in cash or publicly traded common stock when and if declared by the Board of Directors. As of December 31, 2021, no dividends have been declared. Dividends in arrears on the outstanding preferred shares total $412,872 as of December 31, 2021.

 

Holders of the Preferred Stock have the right to convert their shares of Preferred Stock into an equal number of shares of Common Stock of the Company. In addition, Preferred Stock holders have the right to vote the number of shares into which their shares are convertible into Common Stock. Such preferred shares will automatically convert into one share of Common Stock at the close of a public offering of Common Stock by the Company provided the Company receives gross proceeds of at least $1,000,000, and the initial offering price of the Common Stock sold in such offering is equal to or in excess of $1 per share. The Company is obligated to reserve an adequate number of shares of its common stock to satisfy the conversion of all the outstanding Series A Preferred Stock. There were no shares converted during the reporting period. So long as any share of Series A Preferred Stock is outstanding, the Company is prohibited from declaring dividends or other distributions related to its Common Stock or purchasing, redeeming or otherwise acquiring any of the Common Stock.

  

-8-

 

 

NOTE D - INCOME TAXES AND AVAILABLE CARRYFORWARD

 

As of December 31, 2021, the Company had consolidated income tax net operating loss ("NOL") carryforwards for federal income tax purposes of approximately $588,000. NOL arising before December 31, 2020 will expire in various years ending through the year 2035 and for losses arising in taxable years beginning after December 31, 2020, the deduction is limited to 80% of taxable income and can be carried forward indefinitely. The utilization of certain loss carryforwards are limited under Section 382 of the Internal Revenue Code.

 

The components of the provision for income tax (expense) attributable to continuing operations are as follows:

 

  
Six Months
12/31/2021
  

Six Months

12/31/2020

 

Current

        

Federal

 $0  $0 

State

  0   0 
  $0  $0 

Deferred

        

Federal

 $(31,587) $(22,605)

State

  (6,535)  (4,676)
  $(38,122) $(27,281)

Total Income Tax Benefit / (Expense)

 $(38,122) $(27,281)

 

Deferred income taxes reflect the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities are as follows:

 

  

Non-Current

 

Deferred tax assets

    

NOL and contribution carryforwards

 $149,147 

Share based payments

  4,988 

Lease liabilities - operating leases

  185,468 

Accrued compensated absences

  5,807 

Accrued bonus

  4,158 

Allowance for doubtful accounts

  2,384 

Total deferred tax assets

  351,952 
     

Deferred tax (liabilities)

    

Right-of-use-assets - operating leases

  (201,460)

Excess of tax over book depreciation

  (36,224)

Total deferred tax (liabilities)

  (237,684)
     

Total deferred tax asset

  114,268 

Valuation Allowance

  (31,960)

Net Deferred Tax Asset

 $82,308 
     
The change in the valuation allowance is as follows:    

June 30, 2021

 $- 

December 31, 2021

 $(31,960)
  $(31,960)

 

- 9-

 

Income taxes for the six months ended December 31, 2021 and 2020 differ from the amounts computed by applying the effective income tax rate of 25.35%, to income before income taxes as a result of the following:

 

  

Six Months

Decemember 31, 2021

  

Six Months

December 31, 2020

 

Expected (provision) at US statutory rate

 $(2,739) $(67,345)

State income tax net of federal (provision)

  (567)  (13,934)

Nondeductible Expense

  (1,854)  (2,303)

Change in estimates of loss carryforward

  (1,002)  (337)

Change in valuation allowance

  (31,960) $56,638 

Income Tax (Expense)

 $(38,122) $(27,281)

 

The earliest tax year still subject to examination by a major taxing jurisdiction is fiscal year end June 30, 2019.

 

The Company performed a review of its uncertain tax positions in accordance with Accounting Standards Codification ASC 740- 10 "Uncertainty in Income Taxes". In this regard, an uncertain tax position represents the Company's expected treatment of a tax position taken in a filed tax return, or planned to be taken in a future tax return, that has not been reflected in measuring income tax expense for financial reporting purposes. As a result of this review, the Company concluded that at this time there are no uncertain tax positions, and there has been no cumulative effect on retained earnings.

  

 
NOTE E - LINE OF CREDIT

 

A line of credit was procured in June 2021, with a bank. The limit for this line of credit is $250,000 as well. Terms of the Line of credit include and an interest rate that fluctuates at prime plus a half of point, interest only. The line of credit matures on June 30, 2022.

 

- 10-

 
Interest expense for the years ended June 30, 2021 and the period ending December 31, 2021, was $0 and $0, respectively.

 

The line of credit is guaranteed by Justice W. Anderson, President and Chief Executive Officer.

 

 
NOTE F - PAYCHECK PROTECTION PROGRAM LOAN

 

The Company applied for a loan with the Small Business Administration (the "SBA") Paycheck Protection Program ("PPP") of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the "CARES Act") in the amount of $201,000 (the "Loan"). The Loan was funded on April 13, 2020. The Company used the proceeds of the Loan for covered payroll costs, rent and utilities in accordance with the relevant terms and conditions of the CARES Act.

 

The Loan, which is evidenced by a promissory note (the "Note"), has a two-year term, matures on April 13, 2022, and bear interests at a rate of 1.00% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (discussed below), will commence seven months from the date the Note was signed and funded. The Company did not provide any collateral or guarantees for the Loan, nor did they pay any facility charge to obtain the Loan. The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company may prepay the principal of the Loan at any time without incurring any prepayment charges.

 

The Loan may be forgiven partially or fully if the Loan proceeds are used for covered payroll costs, rent and utilities, provided that such amounts are incurred during the eight-week period that commenced on April 13, 2020. Any forgiveness of the Loan will be subject to approval by the SBA and will require the Companies to apply for such treatment.

 

The loan was forgiven by the SBA in May of 2021.

 

 
NOTE G - RECENT ACCOUNTING PRONOUNCEMENTS

 

In June 2016, the F ASB issued Accounting Standards Update No. 2016- 13, Financial Instruments - Credit Loss (Topic 326) ( 44ASU 2016- 13"), which updates the guidance on recognition and measurement of credit losses for financial assets. The new requirements, known as the current expected credit loss model ("CECL ") will require entities to adopt an impairment model based on expected losses rather than incurred losses. ASU 2016- 13 must be adopted on a modified-retrospective approach. This update was effective for fiscal years beginning after December 15, 2020 including interim periods within those fiscal years. In October 2019, the FASB approved an extension for all non-SEC filers, including small reporting companies, to extend the effective date to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Therefore, the effective date for this update will be July 1, 2023. The Company is currently evaluating the potential impact of the adoption of the new standard on its consolidated statements of financial condition and results of operations.

 

 
NOTE H - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

 

Operating leases

 

In June 2015, the Company entered into a lease agreement to lease certain office equipment with a lease term of 63 months. The lease contains a renewal option to extend the term for successive one year periods. Initial rent amount was $1,079 per month, with increases each year no more than 3%. In applying ASC 842, the Company used a lease term of 63 months and an incremental borrowing rate of 5.5% which was the borrowing rate on the Company’s line of credit with a financial institution with all accounts and general intangibles. This lease expired in September 2020. As such, the right-of-use asset has been fully amortized and its related lease liability extinguished at September 30, 2020.

 

- 11-

 
In February 2018, the Company entered in a lease agreement to lease warehouse space with a lease term of 39 months. The Company paid no rent for the first three months of the lease, pays $2,936 per month for the next 12 months, $3,024 per month for the next 8 months, $3,019 per month for the next 4 months, and $3,109 for the last 12 months. In applying ASC 842, the Company uses a lease term of 39 months and an incremental borrowing rate of 5.5% which was the borrowing rate on the Company’s line of credit with a financial institution. This lease expired in April 2021. As such, the right-of-use asset has been fully amortized and its related lease liability extinguished at April 30, 2021.

 

In August 2020, the Company entered into a lease agreement to lease certain office equipment with a lease term of 63 months. The lease renews on a month-to-month basis and contains an option to purchase the equipment at fair market value or return the equipment. Historically, the Company has not exercised the option to purchase at the end of the initial lease term for similar leases and simply returned the equipment at the end of the initial lease term. Initial rent amount was $574 per month. In applying ASC 842, the Company uses a lease term of 63 months and an incremental borrowing rate of 4.25% which was the borrowing rate on the Company’s line of credit with a financial institution.

 

In January 2021, the Company entered in a lease agreement to lease warehouse space with a lease term of 64 months. The Company paid no rent for the first four months of the lease and pays $4,792.50 per month beginning the 5th month of the lease. Rent will increase each succeeding year by no less than 2% but not more than 5%. The rent amount includes common area maintenance charges which are considered nonlease components. In applying ASC 842, the Company is electing to account for nonlease components as being related to the lease component. In addition, the Company uses a lease term of 64 months and an incremental borrowing rate at prime rate of 3.25% which was the borrowing rate on the Company’s recent line of credit with a financial institution.

 

In January 2021, the Company entered in a lease agreement to lease office space with a lease term of 64 months. The Company paid no rent for the first four months of the lease and pays $9,372 per month beginning the 5th month of the lease. Rent will increase each succeeding year by no less than 2% but not more than 5%. The rent amount includes common area maintenance charges which are considered nonlease components. In applying ASC 842, the Company is electing to account for nonlease components as being related to the lease component. The Company also incurred initial direct cost of $114,083 related to existing improvements in the leased space. This initial direct cost has been included in determining the initial ROU asset and liability amounts. In addition, the Company uses a lease term of 64 months and an incremental borrowing rate at prime rate of 3.25% which was the borrowing rate on the Company’s recent line of credit with a financial institution.

 

The following is information related to the Company’s right-of-use assets and liabilities for its operating leases:

 

ROU assets - operating leases obtained in exchange for lease liabilities - operating leases $973,081 
Amortization of ROU assets since lease inception $(178,209)
ROU assets - operating leases at December 31, 2021 $794,872 
Lease liabilities - operating leases on adoption date and increase in lease liabilities $973,081 
Payments on lease liabilities  (241,305)
Lease liabilities - operating leases on December 31, 2021  731,776 
Lease liabilities - operating leases due in the 12 months ending December 31, 2022  158,247 
Lease liabilities - operating leases due after December 31, 2022 $573,528 

 

- 12-

 

Variable lease expense was $50,020 and $8,386 for the three months ended December 31, 2021 and 2020, respectively. Variable lease expense was $100,041 and $22,516 for the six months ended December 31, 2021 and 2020, respectively.

 

Weighted average remaining lease term was 4.24 years and weighted average discount rate was 3.29% at December 31, 2021.

 

 
NOTE I - CONTINGENCY

 

At the time of release of these financial statements, the United States is experiencing a National Emergency related to persistent health issues. Management is unable to quantify the potential duration and economic impact of mandated closures by our National, State or Local governments.

 

 
NOTE J - SUBSEQUENT EVENTS

 

We have evaluated subsequent events through February 10, 2022, which is the date the financial statements were available to be issued.

 

ITEM 2.         MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

General

 

You should read the following discussion and analysis in conjunction with the unaudited Condensed Financial Statements and Notes thereto appearing elsewhere in this report.

 

This Report on Form 10-Q, including Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements. When used in this report, the words "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "hope," "believe" and similar expressions, variations of these words or the negative of those words, and, any statement regarding possible or assumed future results of operations of the Company's business, the markets for its products, anticipated expenditures, regulatory developments or competition, or other statements regarding matters that are not historical facts, are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding events, conditions and financial trends including, without limitation, business conditions in the skin and wound care market and the general economy, competitive factors, changes in product mix, production delays, product recalls, manufacturing capabilities, the impact of the COVID-19 pandemic on the Company’s sales, operations and supply chain and other risks or uncertainties detailed in other of the Company's Securities and Exchange Commission filings. Such statements are based on management's current expectations and are subject to risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company's actual plan of operations, business strategy, operating results and financial position could differ materially from those expressed in, or implied by, such forward-looking statements.

 

-13-

 

Recent Developments

 

In fiscal 2021 and 2022 to date, management has expanded on the services and options the Company provides for its customers. A new website for the Extremit-Ease product was created and is operational (www.extremitease.com). Management is also working on new Business to Customer (B to C) channels to provide Retail customers better opportunity to purchase our products. The Company also expanded its facilities in January 2021, moving into approximately 18,000 square feet of office and warehouse space. This move brought the Company back under a single roof. This has already proven to be very beneficial to our operations. In fiscal 2020, AMERX’s Extremit-Ease Compression Garment line expanded with the introduction of a Tan version of the garment and matching liner.

 

Impact of COVID-19 on Our Business

 

The financial effects of the COVID-19 pandemic started showing their impact on our Company in March of 2020. Due to the timing of these events, the full effect of COVID-19 on our business cannot yet be fully quantified. We have felt the effects of the COVID-19 pandemic in our operations, as management continues to dedicate time and effort researching, discussing and implementing policies and procedures necessary to navigate through the ever changing landscape the COVID-19 pandemic has and continues to provide. As an essential business, management was tasked with remaining open, while keeping our employees safe, and providing our customers, who were still able to actively provide healthcare services, with the products they need.

 

Updating the effects of COVID-19 on our business, currently we have seen fluctuations in our market due to the latest Omicron variant of the COVID-19 virus. The virius’s presence has caused patients to continue to cancel appointments and the medical market to restrict access to elective surgeries. We continue to monitor operations, and are still implementing policies and procedures to keep all our employees as safe as possible. Management does not believe it will truly be able to assess the affects of COVID-19 at this time or in the future, with any certainty.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

The Company's condensed consolidated financial statements have been prepared in accordance with standards of the Public Company Accounting Oversight Board (United States), which require the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosures. A summary of those significant accounting policies can be found in the Notes to the Consolidated Financial Statements included in the Company's annual report on Form 10-K, for the year ended June 30, 2021, which was filed with the Securities and Exchange Commission on October 8, 2021, and as contained in the amendment of the Company's annual report on Form 10-K/A, as filed with the Securities and Exchange Commission on November 12, 2021, which contain certain restatements to the June 30, 2021 financial statements. The estimates used by management are based upon the Company's historical experiences combined with management's understanding of current facts and circumstances. Certain of the Company's accounting policies are considered critical as they are both important to the portrayal of the Company's financial condition and the results of its operations and require significant or complex judgments on the part of management. We believe that the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our consolidated financial statements.

 

-14-

 

Accounts Receivable Allowance

 

Accounts receivable allowance reflects a reserve that reduces our customer accounts and receivable to the net amount estimated to be collectible. The valuation of accounts receivable is based upon the credit-worthiness of customers and third-party payers as well as historical collection experience. Allowances for doubtful accounts are recorded as a selling, general and administrative expense for estimated amounts expected to be uncollectible from third-party payers and customers. The Company bases its estimates on its historical collection experience, current trends, credit policy and on the analysis of accounts by aging category. At December 31, 2021, and June 30, 2021, our allowance for doubtful accounts totaled $4,925 and $9,408, respectively.

 

Advertising and Marketing

 

The Company uses several forms of advertising, including sponsorships to agencies who represent the professionals in their respective fields. The Company expenses these sponsorships over the term of the advertising arrangements on a straight line basis. Other forms of advertising used by the Company include professional journal advertisements, distributor catalogs, website and mailing campaigns. These forms of advertising are expensed when incurred.

 

Deferred Income Taxes

 

Deferred income taxes are recognized for the expected tax consequences in future years for differences between the tax bases of assets and liabilities and their financial reporting amounts, based upon enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. The Company accounts for income taxes under Topic 740 - Income Tax in the Accounting Standards Codification. A valuation allowance is used to reduce deferred tax assets to the net amount expected to be recovered in future periods. The estimates for deferred tax assets and the corresponding valuation allowance require us to exercise complex judgments. We periodically review and adjust those estimates based upon the most current information available. The Company had a valuation allowance of $31,960 as of December 31, 2021 and $0 as of June 30, 2021, respectively. Because the recoverability of deferred tax assets is directly dependent upon future operating results, actual recoverability of deferred tax assets may differ materially from our estimates.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with the Financial Accounting Standards Board's (FASB) release of Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) which requires that five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

Stock Based Compensation

 

Stock based compensation is accounted for in accordance with Topic 718 - Compensation - Stock Compensation in the Accounting Standards Codification. All share-based payments to employees, including grants of employee stock options, are to be recognized in the statement of operations based upon their fair values. Topic 718 rescinds the acceptance of pro forma disclosure.

 

-15-

 

FINANCIAL CONDITION

 

As of December 31, 2021 the Company's principal sources of liquid assets included cash of $806,574, inventories of $1,035,515, and net accounts receivable of $418,591. The Company also has $280,840 in Certificate of Deposits. The Company had net working capital of $2,178,467, and long-term lease liability of $573,528, at December 31, 2021.

 

During the six months ended December 31, 2021 cash decreased from $1,226,522 as of June 30, 2021, to $806,574. Operating activities used cash of $291,633 during the period. Investing activities used cash of $52,208. Financing activities used cash of $76,107.

 

The Company reflected a net non-current deferred tax asset of $82,308, at December 31, 2021. Because the recoverability of deferred tax assets is directly dependent upon future operating results, actual recoverability of deferred tax assets may differ materially from our estimates.

 

RESULTS OF OPERATIONS

 

Comparison of the three and six months ended December 31, 2021 and 2020.

 

Net sales during the quarter ended December 31, 2021, were $1,330,636 as compared to the previous year's quarter net sales of $1,174,405, an increase of $156,231, or approximately 13%. We believe increased sales were driven by increases in our customer base, as well as current customers taking advantage of new program offerings. Net sales during the six months ended December 31, 2021, were $2,520,613 as compared to the previous year's period net sales of $2,420,648, an increase of $99,965, or approximately 4%. We believe increased sales were driven by increases in our customer base, as well as current customers taking advantage of new program offerings.

 

Gross profit during the quarter ended December 31, 2021, was $918,722 as compared to $845,834 during the quarter ended December 31, 2020, an increase of $72,888 or 9%. As a percentage of net sales, gross profit was approximately 69% in the quarter ended December 31, 2021, and approximately 72% in the corresponding quarter in 2020. The decrease in profit was a result, primarily related to a one time sale, at low margin. Gross profit during the six months ended December 31, 2021, was $1,780,446 as compared to $1,757,756 during the six months ended December 31, 2020, an increase of $22,690 or 1%. As a percentage of net sales, gross profit was approximately 71% in the six months ended December 31, 2021, and approximately 73% in the corresponding period in 2020.

 

Operating expenses during the quarter ended December 31, 2021 were $972,632, consisting of $497,261 in salaries and benefits and $475,371 in selling, general and administrative expenses. This compares to operating expenses during the quarter ended December 31, 2020 of $740,959, consisting of $414,467 in salaries and benefits; and $326,492 in selling, general and administrative expenses. Expenses for the quarter ended December 31, 2021, increased by $231,672 or approximately 31% compared to the corresponding quarter in 2020. Salaries and Benefits increased as a result of hiring additional sales support staff and warehouse support, as well as increased salaries driven by the current economies of the available workforce. Operating expenses increased primarily due to increases in marketing expenses, distribution fees associated with a new customer and rent expense from our new offices. Operating expenses during the six months ended December 31, 2021 were $1,768,472, consisting of $936,721 in salaries and benefits and $831,751 in selling, general and administrative expenses. This compares to operating expenses during the six months ended December 31, 2020 of $1,436,333, consisting of $826,721 in salaries and benefits; and $609,612 in selling, general and administrative expenses. Expenses for the six months ended December 31, 2021, increased by $332,139 or approximately 23% compared to the corresponding quarter in 2020. Salaries and Benefits increased as a result of hiring additional sales support staff and warehouse support, as well as increased salaries driven by the current economies of the available workforce. Operating expenses increased primarily due to increases in marketing expenses, distribution fees associated with a new customer, and rent expense from our new offices.

 

-16-

 

Operating profit decreased by $158,784 to an operating loss of $53,909 for the quarter ended December 31, 2021, as compared to an operating profit of $104,875 in the comparable quarter of the prior year. The decrease in net income for the three month period, of the comparable quarter of the prior year before income taxes was primarily attributable to the increase in marketing expenses and rent associated with our new offices. Operating profit decreased by $309,449 to an operating profit of $11,974 for the six months ended December 31, 2021, as compared to an operating profit of $321,423 in the comparable six months of the prior year. The decrease in net income for the six month period, of the comparable six month’s of the prior year before income taxes was primarily attributable to the increase in marketing expenses and rent associated with our new offices.

 

ITEM 4. CONTROLS AND PROCEDURES

 

(a)

Evaluation of Disclosure Controls and Procedures

 

Management of the Company, with the participation of the Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 as of the end of the period covered by this report. Based on that evaluation, management, including the Chief Executive and Chief Financial Officer, has concluded that, as of the end of the period covered by this report, the Company's disclosure controls and procedures were not effective in ensuring that all material information relating to the Company required to be disclosed in this report has been made known to management in a timely manner and ensuring that this information is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and regulations, because of the identification of a material weakness in our internal controls over financial reporting, identified below, which we view as an integral part of our disclosure controls and procedures.

 

(b)

Changes in Internal Controls Over Financial Reporting

 

As previously reported, our annual assessment of the internal controls over financial reporting as of June 30, 2021 revealed a deficiency that we consider to be a material weakness: inadequate segregation of duties consistent with control objectives.

 

During fiscal 2022, the Company will continue to address changes needed to improve segregation of duties consistent with control objectives. We have added staff to grow sales. We expect that increased sales will enable us to add support staff, specifically in the accounting and shipping departments. A secondary effect of adding more staff will address needed improvements in segregation of duties consistent with control objectives.

 

PART II. OTHER INFORMATION

 

ITEM 5. OTHER INFORMATION

 

-17-

 

ITEM 6. EXHIBITS

 

 

(A)

EXHIBITS

 

 //

10.1

Restated and Amended Executive Employment Agreement effective July1, 2021 between Justice W. Anderson, Procyon Corporation and AMERX Health Care Corporation.

 // 10.2

Restated and Amended Executive Employment Agreement effective July1, 2021 between James B. Anderson, Procyon Corporation and AMERX Health Care Corporation.

// 10.3 Restated and Amended Executive Employment Agreement effective July1, 2021 between George O. Borak, Procyon Corporation and AMERX Health Care Corporation.
++ 10.5 Business Line of Credit - Loan Agreement dated June 10, 2021
++ 10.6 Business Line of Credit - Promissory Note dated June 10, 2021
** 10.7 Lease, effective January 15, 2021.
** 10.8 Lease, effective January 15, 2021.
  31.1 Certification of Justice W. Anderson pursuant to Exchange Act Rule 13a-14(a)/15d-14(a)
  31.2 Certification of James B. Anderson pursuant to Exchange Act Rule 13a-14(a)/15d-14(a)
  32.1 Certification Pursuant to 18 U.S.C.§1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002
  101.1* The following materials from the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2021, formatted in iXBRL (Inline Extensible Business Reporting Language): (I) the Condensed Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Consolidated Statements of Cash Flows, and (iv) the Notes to Condensed Consolidated Financial Statements
  104 Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)
  * Furnished, not filed
  // Incorporated by reference to the Company’s form 8-K filed on or about July 28, 2021.
  ++ Incorporated by reference to the Company’s form 10-K filed on or about October 28, 2021.
  ** Incorporated by reference to the Company’s form 8-K filed on or about February 28, 2021.

      

-18-

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

 

 

 

PROCYON CORPORATION

 

February 14, 2022

By:

/s/ JUSTICE W. ANDERSON

 

Date

 

Justice W. Anderson, Chief Executive Officer

 

 

-19-